After announcements by US authorities about allowing the rivals of Reckitt Benckiser to develop generic versions of their heroin substitute, the shares of the company faced a shortfall of about 3%.
As per sources, the pharmaceuticals division of the consumer health goods company earns the maximum of its profit from Suboxone. It is a cure that consists of buprenorphine that help people who have an addiction to opiates cope. This treatment helps them in stopping the intake.
The competitors were being strongly opposed by the company since the expiry of its unshared status in 2009. As per reports, the company agrees to the fact about getting informed by the Food and Drug Administration about the approval of two generic versions of Suboxone tablets in America. It also was informed about the reference of the company to the Federal Trade Commission.
Sources said two generic versions of Reckitt Benckiser's heroin addiction drug were approved by the US authorities. However, they disapproved its proposal of obstructing the products of the competitors on the basis of need of tougher packaging rules for the protection of children. The reports lowered the shares of Reckitt Benckiser by 3%.
